What is Wallife?
Founded in 2020 and headquartered in Rome, Italy, Wallife operates at the intersection of insurance technology and cutting-edge scientific progress. The company specializes in providing protection against risks associated with technological innovation and scientific advancements, specifically focusing on three key areas: genetics, biometrics, and biohacking. Wallife aims to offer novel insurance solutions tailored to the unique challenges and opportunities presented by these rapidly developing fields, addressing the individual's exposure to risks stemming from future scientific and technological breakthroughs.
How much funding has Wallife raised?
Wallife has raised a total of $17.1M across 2 funding rounds:
Angel/Seed
$4.8M
Series A
$12.3M
Angel/Seed (2022): $4.8M, investors not publicly disclosed
Series A (2022): $12.3M led by Aptafin
Key Investors in Wallife
Aptafin
Aptafin is an entity involved in the company's Series A funding, suggesting a strategic interest in Wallife's insurtech innovations.
What's next for Wallife?
The substantial enterprise-level backing and recent strategic investment indicate a strong confidence in Wallife's innovative business model and its capacity to address emerging risks. This capital infusion is expected to fuel further research and development, enhance product offerings, and expand market reach. Wallife is poised to become a leader in specialized insurance solutions, leveraging its focus on genetics, biometrics, and biohacking to provide comprehensive protection in an increasingly complex technological world. The company's strategic positioning suggests a future focused on scaling operations and solidifying its unique market niche.
See full Wallife company page
